Esophageal Adenocarcinoma Methods and Protocols

(sharon) #1

228



  1. Lee SH, Zhou S, Zhou T, Hong G (2016)
    Sanger sequencing for BRCA1 c.68_69del,
    BRCA1 c.5266dup and BRCA2 c.5946del
    mutation screen on pap smear cytology sam-
    ples. Int J Mol Sci 17(2):229. https://doi.
    org/10.3390/ijms17020229

  2. Tu B, Cha N, Yang R, Ng J, Hurley CK (2013)
    A one-step DNA sequencing strategy to HLA
    type hematopoietic stem cell donors at recruit-
    ment – rethinking typing strategies. Tissue
    Antigens 81(3):150–160. https://doi.
    org/10.1111/tan.12072

  3. Renaud M, Marcel C, Rudolf G, Schaeffer M,
    Lagha-Boukbiza O, Chanson JB, Chelly J,
    Anheim M, Tranchant C (2016) A step toward
    essential tremor gene discovery: identification
    of extreme phenotype and screening of HTRA2
    and ANO3. BMC Neurol 16(1):238. https://
    doi.org/10.1186/s12883-016-0748-3

  4. Liu Y, Asan, Ma D, Lv F, Xu X, Wang J, Xia W,
    Jiang Y, Wang O, Xing X, Yu W, Wang J, Sun J,
    Song L, Zhu Y, Yang H, Wang J, Li M (2017)
    Gene mutation spectrum and genotype-pheno-
    type correlation in a cohort of Chinese osteo-
    genesis imperfecta patients revealed by targeted
    next generation sequencing. Osteoporos Int.
    https://doi.org/10.1007/
    s00198-017-4143-8

  5. Jinda W, Taylor TD, Suzuki Y, Thongnop-
    pakhun W, Limwongse C, Lertrit P, Trinavarat
    A, Atchaneeyasakul LO (2017) Whole exome
    sequencing in eight Thai patients with Leber
    congenital amaurosis reveals mutations in the
    CTNNA1 and CYP4V2 genes. Invest
    Ophthalmol Vis Sci 58(4):2413–2420.
    https://doi.org/10.1167/iovs.16-21322

  6. Wang DN, Wang ZQ, Yan L, He J, Lin MT,
    Chen WJ, Wang N (2017) Clinical and muta-
    tional characteristics of Duchenne muscular
    dystrophy patients based on a comprehensive
    database in South China. Neuromuscul Disord
    27(8):715–722. https://doi.org/10.1016/j.
    nmd.2017.02.010

  7. Laarabi FZ, Ratbi I, Elalaoui SC, Mezzouar L,
    Doubaj Y, Bouguenouch L, Ouldim K,
    Benjaafar N, Sefiani A (2017) High frequency
    of the recurrent c.1310_1313delAAGA
    BRCA2 mutation in the North-East of
    Morocco and implication for hereditary breast-
    ovarian cancer prevention and control. BMC
    Res Notes 10(1):188. https://doi.
    org/10.1186/s13104-017-2511-2

  8. Chen J, Peng P, Du Y, Ren Y, Chen L, Rao Y,
    Wang W (2017) Early detection of multidrug-
    and pre-extensively drug-resistant tuberculosis
    from smear-positive sputum by direct sequenc-


ing. BMC Infect Dis 17(1):300. https://doi.
org/10.1186/s12879-017-2409-6


  1. Dougherty BA, Lai Z, Hodgson DR, Orr
    MCM, Hawryluk M, Sun J, Yelensky R,
    Spencer SK, Robertson JD, Ho TW, Fielding
    A, Ledermann JA, Barrett JC (2017) Biological
    and clinical evidence for somatic mutations in
    BRCA1 and BRCA2 as predictive markers for
    olaparib response in high-grade serous ovarian
    cancers in the maintenance setting. Oncotarget
    8(27):43653–43661. https://doi.org/
    10.18632/oncotarget.17613

  2. Tiedje V, Ting S, Herold T, Synoracki S,
    Latteyer S, Moeller LC, Zwanziger D, Stuschke
    M, Fuehrer D, Schmid KW (2017) NGS based
    identification of mutational hotspots for tar-
    geted therapy in anaplastic thyroid carcinoma.
    Oncotarget 8(26):42613–42620. https://doi.
    org/10.18632/oncotarget.17300

  3. Garcia E, Hayden A, Birts C, Britton E, Cowie
    A, Pickard K, Mellone M, Choh C, Derouet M,
    Duriez P, Noble F, White MJ, Primrose JN,
    Strefford JC, Rose-Zerilli M, Thomas GJ, Ang
    Y, Sharrocks AD, Fitzgerald RC, Underwood
    TJ, Consortium O (2016) Authentication and
    characterisation of a new esophageal adenocar-
    cinoma cell line: MFD-1. Sci Rep 6:32417.
    https://doi.org/10.1038/srep32417

  4. Streppel MM, Lata S, DelaBastide M,
    Montgomery EA, Wang JS, Canto MI,
    Macgregor-Das AM, Pai S, Morsink FH,
    Offerhaus GJ, Antoniou E, Maitra A,
    McCombie WR (2014) Next-generation
    sequencing of endoscopic biopsies identifies
    ARID1A as a tumor-suppressor gene in
    Barrett’s esophagus. Oncogene 33(3):347–
    357. https://doi.org/10.1038/onc.2012.586

  5. Ferrer-Torres D, Nancarrow DJ, Kuick R,
    Thomas DG, Nadal E, Lin J, Chang AC,
    Reddy RM, Orringer MB, Taylor JM, Wang
    TD, Beer DG (2016) Genomic similarity
    between gastroesophageal junction and
    esophageal Barrett’s adenocarcinomas.
    Oncotarget 7(34):54867–54882. https://
    doi.org/10.18632/oncotarget.10253

  6. Zou H, Osborn NK, Harrington JJ, Klatt KK,
    Molina JR, Burgart LJ, Ahlquist DA (2005)
    Frequent methylation of eyes absent 4 gene in
    Barrett’s esophagus and esophageal adenocar-
    cinoma. Cancer Epidemiol Biomark Prev
    14(4):830–834. https://doi.org/10.1158/
    1055-9965.epi-04-0506

  7. Taniere P, Martel-Planche G, Maurici D,
    Lombard-Bohas C, Scoazec JY, Montesano R,
    Berger F, Hainaut P (2001) Molecular and
    clinical differences between adenocarcinomas


Katherine T. W. Lee et al.
Free download pdf